Special Issue "HIV and SARS-CoV-2 Pathogenesis and Vaccine Development"
Deadline for manuscript submissions: closed (15 April 2022) | Viewed by 32448
The discovery of efficient antiretroviral drugs has been crucial in the struggle against HIV (particularly HIV-1), leading to the management of chronic infection with a long-term life expectancy. However, there is one major field of research where progress is not at the expected level—namely HIV vaccine, whether preventive or therapeutic. Preventive vaccines have been largely investigated but have been hampered by the high variability of the virus with a lack of cross neutralization. Therapeutic vaccines were launched by Jonas Salk very early in the history of HIV/AIDS and represent an interesting option for viral cure possibly in association with purging agents (“shock and kill”). Most aim to stimulate CD8+ T-cell reactivity against conserved epitopes of the archived virus; it is now clear that it is necessary to take into account the genetic background of patients and the role of immune checkpoints like PD-1. It is also important to consider a new therapeutic option based on silencing of the virus (“block and lock”).
SARS-CoV-2 virus has emerged from the animal reservoir at the end of 2019 and is now associated with the worst pandemic in humans since “Spanish flu” in 1918. There is a growing understanding of the virus in virology, and numerous potential vaccines based on neutralization of the spike using different techniques (mRNA, recombinant adenovirus, inactivated virus, etc.) are being investigated; however, no efficient anti-SARS-CoV-2 drug has been identified so far, and there is a race to develop an antiviral treatment for this viral infection.
This Special Issue is open to all researchers involved in the struggle against HIV and SARS-CoV-2; original articles and reviews are welcome mainly in the field of vaccine development but also in pathogenesis and antiviral drugs.
Dr. Herve J A Fleury
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- antiviral drugs
- animal models